Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
NCT05719311
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Orlando, Florida, United States
View Trial DetailsNCT Number: NCT01424696
Cystic fibrosis (CF) is a life-shortening disease that causes breathing and digestive problems, but can now be diagnosed at the time of birth. Lung function is very hard to measure in infants, but growth is not. In this study the investigators aim to define growth in infants with CF in the first year of life with research quality precision and to understand factors that interfere with good growth.
Pancreatic enzyme replacement therapy (PERT) will be also be studied in a subgroup of infants. Two different doses of PERT will be evaluated for improving fat and nitrogen absorption in infants with CF.
Looking for future studies?
Notify MeUp to 3 month
All sexes
Observational
University of Alabama at Birmingham, Birmingham, Alabama, United States
Newborn screening (NBS) for cystic fibrosis (CF) has decreased the prevalence of malnutrition in infancy, but suboptimal nutrition still persists. In one study, 60% of infants diagnosed by NBS achieved their birth weight percentile by two years of age, while 40% did not. The many factors that contribute to this poor growth have not been defined and persist despite pancreatic enzyme supplementation. Although published guidelines for the clinical management of infants with cystic fibrosis in the U.S. and Europe exist, there is an alarming scarcity of evidence to dictate care. In order to proceed with large scale randomized studies to evaluate the range of interventions for infants with CF, we need to not only develop precise techniques for measuring growth but also pursue unexplored factors that may contribute to poor growth.
This is a multi-center observational clinical study with a nested interventional PERT sub-study. The observational study was designed to follow in a prospective manner incident cases of CF for up to 12 months. The PERT sub-study is a randomized, double-blind, crossover sub-study designed to evaluate the efficacy and safety of two doses of PERT (pancreatic enzyme replacement therapy) for improving coefficient of fat absorption (CFA) in the stool of infants with CF. The PERT sub-study was unable to enroll and closed. No results available.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Observational Study
Inclusion criteria
AND
Exclusion criteria
Time frame: one year
To define and describe incremental weight gain and linear growth in the first year of life utilizing research quality growth measures that will be applicable as efficacy outcomes for future interventional studies in infants with CF
Seattle Children's Hospital
Other
Baby Observational and Nutritional Study (BONUS)
Acronym: BONUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05719311
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Orlando, Florida, United States
View Trial DetailsNCT01427712
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Aichi, Japan
View Trial DetailsNCT04966897
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Houston, Texas, United States
View Trial DetailsNCT02279498
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Long Beach, California, United States
View Trial Details